Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Pharmadule Morimatsu AB
AB
Active
Org 5568464910
Hästholmsvägen 28, 131 30
Nacka
Engineering activities and related technical consultancy
·
NACE 7112
Est. 2011 · 15 years old
16 employees
Monitor
Share
Sweden
/
Companies
/
Engineering activities and related technical consultancy
/
Pharmadule Morimatsu AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
1.0B
0.8B
0.5B
0.3B
0B
2020: 0.1B
0.1B
2020
2021: 0.2B (+212% vs 2020)
0.2B
+212%
2021
2022: 0.5B (+126% vs 2021)
0.5B
+126%
2022
2023: 0.8B (+73% vs 2022)
0.8B
+73%
2023
2024: 0.4B (-58% vs 2023)
0.4B
-58%
2024
EBITDA
SEK millions
34M
19M
4M
-11M
-26M
2020: 22M
22M
2020
2021: 13M (-41% vs 2020)
13M
-41%
2021
2022: -14M (-208% vs 2021)
-14M
-208%
2022
2023: 14M (+200% vs 2022)
14M
+200%
2023
2024: 15M (+7% vs 2023)
15M
+7%
2024
Income statement
SEK thousands
Item
2024
2023
2022
2021
2020
Revenue
353 594
841 322
484 728
214 877
68 792
Staff expenses
—
—
—
—
—
EBITDA
14 637
13 858
−14 368
12 623
21 613
Depreciation & amort.
−0
−0
−0
−0
−0
EBIT
14 637
13 858
−14 368
12 623
21 613
Net financials
−29 916
−8 218
−117 900
12 054
−34 483
Profit before tax
10 633
22 984
12 396
20 277
17 985
Tax
−3 145
−4 791
−2 582
−1 971
−762
Net profit
7 488
18 193
9 814
18 306
17 223
Balance sheet
SEK thousands
Item
2024
2023
2022
2021
2020
Total assets
620 300
396 189
307 578
275 242
82 056
Equity
53 860
79 471
61 278
51 464
33 157
Long-term debt
0
0
0
0
0
Short-term debt
550 939
301 218
237 800
219 378
48 899
Total debt
550 939
301 218
237 800
219 378
48 899
Financial ratios
5-year trend
EBITDA margin
4,1 %
This company
15,8 %
Market median
This company
Market median
74% below market
2020
2024
Equity ratio
8,7 %
This company
38,2 %
Market median
This company
Market median
77% below market
2020
2024
Return on equity
13,9 %
This company
18,4 %
Market median
This company
Market median
24% below market
2020
2024
Net profit margin
2,1 %
This company
8,1 %
Market median
This company
Market median
74% below market
2020
2024
Asset turnover
0,57×
This company
1,12×
Market median
This company
Market median
49% below market
2020
2024
Debt / equity
10,52×
This company
0,62×
Market median
This company
Market median
>999% above market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Pharmadule Morimatsu AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
